Compare REAL & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | NKTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 188.9M |
| IPO Year | 2019 | 2020 |
| Metric | REAL | NKTX |
|---|---|---|
| Price | $9.58 | $3.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $17.00 | $11.33 |
| AVG Volume (30 Days) | ★ 4.0M | 683.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $692,845,000.00 | N/A |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $4.71 | $1.63 |
| 52 Week High | $17.39 | $3.65 |
| Indicator | REAL | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 59.65 |
| Support Level | $8.69 | $1.96 |
| Resistance Level | $11.17 | $3.35 |
| Average True Range (ATR) | 0.54 | 0.21 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 60.14 | 84.62 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.